Nyssa Schwager
Duke University(US)Clinical Research Institute(US)Duke Medical Center(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Bacterial Identification and Susceptibility Testing, Antibiotic Use and Resistance, Sepsis Diagnosis and Treatment
Most-Cited Works
- → Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults(2022)22 cited
- → Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers(2022)21 cited
- → Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group(2023)17 cited
- → The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations(2023)13 cited
- → The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions(2023)9 cited
- → Priorities and Progress in Diagnostic Research by the Antibacterial Resistance Leadership Group(2023)5 cited
- → Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.(2016)3 cited
- → Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trial(2025)1 cited
- → 232. Population Pharmacokinetics (PopPK) of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)(2022)